The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial
Open accessAbstract
Importance: Guidelines recommend corticosteroids in patients with IgA nephropathy and persistent proteinuria, but the effects remain uncertain. Objective: To evaluate the efficacy and safety of corticosteroids in patients with IgA nephropathy at risk of progression. Design, Setting, and Participants: The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) study was a multicenter, double-blind, randomized clinical trial designed to recruit 750 participants with IgA nephropathy (proteinuria greater than 1 g/d and estimated glomerular filtration rate [eGFR] of 20 to 120 mL/min/1.73 m2 after at least 3 months of blood pressure control with renin-angiotensin system blockade] and to provide follow-up until 335 primary outcomes occurred. Interventions: Patients were randomized 1:1 to oral methylprednisolone (0.6-0.8 mg/kg/d; maximum, 48 mg/d) (n = 136) or matching placebo (n = 126) for 2 months, with subsequent weaning over 4 to 6 months. Main Outcomes and Measures: The primary composite outcome was end-stage kidney disease, death due to kidney failure, or a 40% decrease in eGFR. Predefined safety outcomes were serious infection, new diabetes, gastrointestinal hemorrhage, fracture/osteonecrosis, and cardiovascular events. The mean required follow-up was estimated to be 5 years. Results: After randomization of 262 participants (mean age, 38.6 [SD, 11.1] years; 96 [37%] women; eGFR, 59.4 mL/min/1.73 m2; urine protein excretion, 2.40 g/d) and 2.1 years' median follow-up, recruitment was discontinued because of excess serious adverse events. Serious events occurred in 20 participants (14.7%) in the methylprednisolone group vs 4 (3.2%) in the placebo group (P = .001; risk difference, 11.5% [95% CI, 4.8%-18.2%]), mostly due to excess serious infections (11 [8.1%] vs 0; risk difference, 8.1% [95% CI, 3.5%-13.9%]; P < .001), including 2 deaths. The primary renal outcome occurred in 8 participants (5.9%) in the methylprednisolone group vs 20 (15.9%) in the placebo group (hazard ratio, 0.37 [95% CI, 0.17-0.85]; risk difference, 10.0% [95% CI, 2.5%-17.9%]; P = .02). Conclusions and Relevance: Among patients with IgA nephropathy and proteinuria of 1 g/d or greater, oral methylprednisolone was associated with an increased risk of serious adverse events, primarily infections. Although the results were consistent with potential renal benefit, definitive conclusions about treatment benefit cannot be made, owing to early termination of the trial. Trial Registration: clinicaltrials.gov Identifier: NCT01560052.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran, D. C., Coppo, R., Cook, H. T., Feehally, J., Roberts, I. S. D., Troyanov, S., Alpers, C. E., Amore, A., Barratt, J., et al. (2009) · Kidney International · doi:10.1038/ki.2009.243 · Cited by 1,235
Self-citationWyatt, R. J., & Julian, B. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1206793 · Cited by 1,222
Coresh, J., Turin, T. C., Matsushita, K., Sang, Y., Ballew, S. H., Appel, L. J., Arima, H., Chadban, S. J., Cirillo, M., Djurdjev, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.6634 · Cited by 988
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.9 · Cited by 966
Intensive supportive care plus immunosuppression in IgA nephropathy
Rauen, T., Eitner, F., Fitzner, C., Sommerer, C., Zeier, M., Otte, B., Panzer, U., Peters, H., Benck, U., Mertens, P. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415463 · Cited by 726
Self-citationRemission of Proteinuria Improves Prognosis in IgA Nephropathy
Reich, H. N., Troyanov, S. A. A., Scholey, J. W., & Cattran, D. C. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050526 · Cited by 639
Self-citationLevey, A. S., Inker, L. A., Matsushita, K., Greene, T., Willis, K., Lewis, E., de Zeeuw, D., Cheung, A. K., & Coresh, J. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.07.030 · Cited by 620
Corticosteroids in IgA nephropathy: a randomised controlled trial
Pozzi, C., Bolasco, P., Fogazzi, G., Andrulli, S., Altieri, P., Ponticelli, C., & Locatelli, F. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03563-6 · Cited by 532
Fellström, B. C., Barratt, J., Cook, H., Coppo, R., Feehally, J., de Fijter, J. W., Floege, J., Hetzel, G., Jardine, A. G., Locatelli, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30550-0 · Cited by 414
Self-citationLe, W., Liang, S., Hu, Y., Deng, K., Bao, H., Zeng, C., & Liu, Z. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr527 · Cited by 411
Self-citationManno, C., Torres, D. D., Rossini, M., Pesce, F., & Schena, F. P. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp356 · Cited by 311
Floege, J., & Amann, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00272-5 · Cited by 306
Self-citationCoppo (2007) · doi:10.1681/asn.2006040347 · Cited by 256
Lv, J., Zhang, H., Chen, Y., Li, G., Jiang, L., Singh, A. K., & Wang, H. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.07.029 · Cited by 238
Self-citationCorticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study
Tesar, V., Troyanov, S., Bellur, S., Verhave, J. C., Cook, H. T., Feehally, J., Roberts, I. S. D., Cattran, D., & Coppo, R. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070697 · Cited by 217
Self-citationCorticosteroid therapy in IgA nephropathy
Lv, J., Xu, D., Perkovic, V., Ma, X., Johnson, D. W., Woodward, M., Levin, A., Zhang, H., & Wang, H. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011111112 · Cited by 190
Self-citationConnell, J. M. C., Whitworth, J. A., Davies, D. L., Lever, A. F., Richards, A. M., & Fraser, R. (1987) · Journal of Hypertension · doi:10.1097/00004872-198708000-00007 · Cited by 188
Barbour, S. J., Cattran, D. C., Kim, S. J., Levin, A., Wald, R., Hladunewich, M. A., & Reich, H. N. (2013) · Kidney International · doi:10.1038/ki.2013.210 · Cited by 164
Self-citationInker, L. A., Mondal, H., Greene, T., Masaschi, T., Locatelli, F., Schena, F. P., Katafuchi, R., Appel, G. B., Maes, B. D., Li, P. K., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.02.042 · Cited by 160
Immunosuppressive agents for treating IgA nephropathy
Vecchio, M., Bonerba, B., Palmer, S. C., Craig, J. C., Ruospo, M., Samuels, J., Molony, D. A., Schena, F. P., & Strippoli, G. F. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003965.pub2 · Cited by 119
Cushing’s syndrome, glucocorticoids and the kidney
Smets, P. M. Y., Meyer, E., Maddens, B., & Daminet, S. (2010) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2010.07.004 · Cited by 105
Lv, J., Zhang, H., Zhou, Y., Li, G., Zou, W.-Z., & Wang, H. (2008) · Nephrology · doi:10.1111/j.1440-1797.2007.00898.x · Cited by 100
Self-citationIntensive Supportive Care plus Immunosuppression in IgA Nephropathy
Floege, J., Rauen, T., & Eitner, F. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1600141 · Cited by 63
Self-citationProgression of IgA Nephropathy under Current Therapy Regimen in a Chinese Population
Li, X., Liu, Y., Lv, J., Shi, S., Liu, L., Chen, Y., & Zhang, H. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01990213 · Cited by 56
Self-citation
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationKalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., & Perkovic, V. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00519-5 · Cited by 1,461
Self-citationEvaluating a New International Risk-Prediction Tool in IgA Nephropathy
Barbour, S. J., Coppo, R., Zhang, H., Liu, Z.-H., Suzuki, Y., Matsuzaki, K., Katafuchi, R., Er, L., Espino-Hernandez, G., Kim, S. J., et al. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.0600 · Cited by 478
Self-citationWheeler, D. C., Toto, R. D., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Pecoits-Filho, R., Correa-Rotter, R., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.033 · Cited by 420
Self-citationLv, J., Wong, M. G., Hladunewich, M. A., Jha, V., Hooi, L. S., Monaghan, H., Zhao, M., Barbour, S., Jardine, M. J., Reich, H. N., et al. (2022) · JAMA · doi:10.1001/jama.2022.5368 · Cited by 354
Self-citation
Metadata
- Authors
- Lv, J., Zhang, H., Wong, M. G., Jardine, M. J., Hladunewich, M., Jha, V., Monaghan, H., Zhao, M., Barbour, S., Reich, H., Cattran, D., Glassock, R., Levin, A., Wheeler, D., Woodward, M., Billot, L., Chan, T. M., Liu, Z.-H., Johnson, D. W., Cass, A., Feehally, J., Floege, J., Remuzzi, G., Wu, Y., Agarwal, R., Wang, H.-Y., Perkovic, V., & for the TESTING Study Group
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2017-08-01
- Volume
- 318
- Issue
- 5
- Pages
- 432
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2741457765
- Cited by
- 540
- References
- 28
- FWCI
- 32.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.